AZD 0754
Alternative Names: AZD-0754Latest Information Update: 23 Feb 2024
At a glance
- Originator AstraZeneca
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Prostate cancer
Most Recent Events
- 19 Feb 2024 Phase-I/II clinical trials in Prostate cancer (Metastatic disease, Hormone refractory, Second-line therapy or more) in USA (IV) (NCT06267729)
- 14 Apr 2023 Preclinical trials in Solid tumours in United Kingdom (Parenteral)
- 14 Apr 2023 Pharmacodynamics data from a preclinical study in Solid tumours presented at the American Association for Cancer Research Annual Meeting (AARC-2023)